Oric Pharmaceuticals, Inc. · NASDAQ:ORIC
Oric Pharmaceuticals — Corporate Update (March 2026)
44 slides from Oric Pharmaceuticals's corporate update, Mar 31, 2026
Slide 1: Rinzimetostat Dose Optimization Data Update
Exhibit 99.1 Rinzimetostat Dose Optimization Data Update March 31, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us”
Slide 3: Agenda and ORIC Participants
Rinzimetostat Dose Optimization Data Update Agenda • Executive Summary • Preclinical Differentiation • Clinical Program Update and Next Steps – Selection of Phase 3 Dose – Preliminary Profile of Phase 3 Dose – Next Steps and Registrational Strategy • Commercial Potential for Himalayas-1 and Beyond •
Slide 4: Executive Summary
Executive Summary
Slide 5: Clinical Pipeline Focused on Advancement of Rinzimetostat and Enozertinib
Clinical Pipeline Focused on Advancement of Rinzimetostat and Enozertinib Discovery / Clinical Phase 3 Program Indication IND Enabling Phase 1/2 Pivotal / Phase 3 Collaboration Initiations PRODUCT CANDIDATES Himalayas-1 • Combination with darolutamide Expected in 1H 2026 Rinzimetostat Potential Pros
Slide 6: Rinzimetostat Continues to Demonstrate Its Potential as a Best-In-Disease Option for Prostate Cancer
Rinzimetostat Continues to Demonstrate Its Potential as a Best-In-Disease New Therapeutic Option for Prostate Cancer • PRC2 inhibitors have shown significant rPFS in mCRPC, comparing favorably to approved & emerging therapies • Rinzimetostat is a next-generation PRC2 inhibitor designed to have best-
Slide 7: PRC2 Inhibitors Are Associated with Significant rPFS in Post-ARPI mCRPC
PRC2 Inhibitors Are Associated with Significant Radiographic Progression-Free Survival in Post-ARPI mCRPC, Comparing Favorably to Available Therapies Therapies for 1L+ mCRPC (Post-ARPI) Treatment Status 5-Month rPFS Median rPFS (months) ® 60% Enzalutamide (Xtandi ) Approved 6.2 ® 65% 8.0 Cabazitaxel
Slide 8: Rinzimetostat + Darolutamide Compares Favorably to Competitor PRC2 Combination and AR Inhibitor Monotherapy
Combination of Rinzimetostat + Darolutamide Compares Favorably to Competitor PRC2 Combination and to AR Inhibitor Monotherapy In Post-Abiraterone mCRPC Rinzimetostat Dose Optimization Update (March 2026) Mevrometostat 1250 mg BID Rinzimetostat 400 mg QD Enzalutamide Fasted + Enzalutamide + Darolutam
Slide 9: Potential to Address Multiple Large Market Opportunities in Prostate Cancer
Rinzimetostat Has the Potential to Address Multiple Large Market Opportunities in Prostate Cancer, with Several Development Opportunities in Other Solid Tumors Potential Rinzimetostat Commercial Opportunity (US Only) Future Development Opportunities 90,000 >$10 billion US Est. Annual US Incidence op
Slide 10: Preclinical Differentiation
Preclinical Differentiation
Slide 11: Next-Generation PRC2 Inhibitor Designed for Best-in-Class Drug Properties
Rinzimetostat: Next-Generation PRC2 Inhibitor Designed for Best-in-Class Drug Properties Potential Best-in-Class PRC2 Inhibitor Landscape in Prostate Cancer CPI-1205 Tazemetostat Mevrometostat Rinzimetostat st st nd rd Key Features (1 gen) (1 gen) (2 gen) (3 gen) Superior potency vs. st 1 gen progra
Slide 12: Superior In Vitro Potency vs. First-Gen PRC2 Inhibitors
Rinzimetostat Demonstrates Superior In Vitro Potency vs. First-Gen PRC2 Inhibitors In Vitro Potency in Prostate Cancer Cells LNCaP CWR22PC (AR-Positive Prostate Cancer Cells) (AR-Positive Prostate Cancer Cells) LNCaP (AR+ Cells) CWR22PC (AR+ Cells) 1.5 1.5 CPI-1205 CPI-1205 Tazemetostat Tazemetostat
Slide 13: PRC2 Epigenetic Dysregulation in Progressive Reprogramming of Prostate Cancers
PRC2 Epigenetic Dysregulation Plays a Key Mechanistic Role During the Progressive Reprogramming of Prostate Cancers Treated with AR Inhibitors PRC2 Role in Prostate Cancer AR Dependent Prostate Cancer AR Independent Prostate Cancer • Prostate cancer cells evade therapies by cellular reprogramming to
Slide 14: Increases AR Signaling and Induces Luminal State to Drive Synergy
Rinzimetostat Increases AR Signaling and Induces Luminal State to Drive Synergy in Prostate Cancer Models Rinzimetostat Impact on AR Signaling Genes and Luminal Markers CRPC Model CSPC Model AR Signaling Genes Luminal Markers AR Signaling Genes Luminal Markers **** **** **** **** Rinzimetostat enhan
Slide 15: Remodels Chromatin to Block Transcription Factor Sites that Drive Lineage Escape
Rinzimetostat Remodels Chromatin to Block Transcription Factor Sites that Drive Lineage Escape Rinzimetostat Impact on Accessibility to Lineage Escape Factors CRPC Model CSPC Model Less accessible More accessible Less accessible More accessible with rinzimetostat with rinzimetostat with rinzimetosta
Slide 16: Increases Progression-Free Survival in Combination with Darolutamide in Xenografts
Rinzimetostat Increases Progression-Free Survival in Combination with Darolutamide in Prostate Cancer Xenograft Tumors Progression-Free Survival in Prostate Cancer Xenografts CRPC Model CSPC Model 100 100 Rinzimetostat + Rinzimetostat + Darolutamide Darolutamide Mevrometostat + Mevrometostat + Darol
Slide 17: Clinical Program Update and Next Steps: Selection of Phase 3 Dose
Clinical Program Update and Next Steps Selection of Phase 3 Dose
Slide 18: Explored in Combination with Darolutamide and Apalutamide in Metastatic CRPC
Rinzimetostat Is Being Explored in Combination with Darolutamide and Apalutamide in Metastatic CRPC Phase 1b, Multicenter, Open-Label Trial (in Collaboration with Bayer and Johnson & Johnson) Rinzimetostat Combination Dose Exploration Rinzimetostat Combination Dose Optimization March 2026 Update Key
Slide 19: Favorable Pharmacokinetic and Pharmacodynamic Profile
Rinzimetostat Demonstrates a Favorable Pharmacokinetic and Pharmacodynamic Profile as a Single Agent and in Combination with Darolutamide Pharmacokinetic and Pharmacodynamic Profile Summary Rinzimetostat Pharmacokinetic Profile Rinzimetostat Pharmacodynamic Profile (Total Plasma Concentration) (H3K2
Slide 20: Phase 1b Trial Enrolled Heavily Pretreated Post-Abiraterone mCRPC Patients
Phase 1b Dose Optimization Trial Enrolled Heavily Pretreated Post-Abiraterone mCRPC Patients Demographics and Baseline Characteristics Rinzimetostat 400 mg QD Rinzimetostat 600 mg QD Characteristic + Darolutamide (n=18) + Darolutamide (n=15) Age, median (range), years 67 (51, 85) 77 (58, 91) Race, W
Slide 21: Generally Well Tolerated with Darolutamide in Post-Abiraterone mCRPC
Rinzimetostat in Combination with Darolutamide Has been Generally Well Tolerated in Post-Abiraterone mCRPC Patients TEAEs Attributed to Rinzimetostat Plus Darolutamide (≥10% Total Incidence) Rinzimetostat 400 mg QD + Darolutamide (n=18) Rinzimetostat 600 mg QD + Darolutamide (n=15) Preferred Term, n
Slide 22: Generally Well Tolerated with Darolutamide in Post-ARPI mCRPC
Rinzimetostat in Combination with Darolutamide Has been Generally Well Tolerated in Post-ARPI mCRPC Patients TEAEs Attributed to Rinzimetostat Plus Darolutamide (≥10% Total Incidence) Rinzimetostat 600 mg QD + Darolutamide (n=35) Rinzimetostat 400 mg QD + Darolutamide (n=37) Preferred Term, n (%) Gr
Slide 23: 400 mg QD with Darolutamide More Tolerable than 600 mg QD
Rinzimetostat 400 mg QD in Combination with Darolutamide Is More Tolerable than 600 mg QD in mCRPC Patients Rinzimetostat Plus Darolutamide Tolerability Summary Rinzimetostat 400 mg QD Rinzimetostat 600 mg QD + Darolutamide + Darolutamide Post-Abiraterone Post-ARPI Post-Abiraterone Post-ARPI (n=18)
Slide 24: Exposure-Response Analyses Support 400 mg QD as RP3D
Rinzimetostat Exposure-Response Analyses Supports 400 mg QD as RP3D Based on Lower Toxicity, Fewer Dose Modifications, and Comparable Efficacy Rinzimetostat Exposure-Response Analyses • Objective: Select the RP3D between 400 mg QD vs 600 mg QD by evaluating relationships between exposure of rinzimet
Slide 25: Clinical Program Update and Next Steps: Preliminary Profile of Phase 3 Dose
Clinical Program Update and Next Steps Preliminary Profile of Phase 3 Dose
Slide 26: Strong Clinical Activity: PSA Response in Post-Abiraterone mCRPC
Rinzimetostat in Combination with Darolutamide Continues to Demonstrate Strong Clinical Activity in Post-Abiraterone mCRPC Patients PSA Response Data of Rinzimetostat 400 mg QD Plus Darolutamide * * * 50 Response Unconfirmed Confirmed PSA50 7/15 (47%) 5/15 (33%) 25 PSA90 2/15 (13%) 1/15 (7%) u50 u50
Slide 27: ctDNA Molecular Response in Post-Abiraterone mCRPC Patients
Rinzimetostat in Combination with Darolutamide Demonstrates Impressive ctDNA Molecular Response in Post-Abiraterone mCRPC Patients ctDNA Molecular Response Data of Rinzimetostat 400 mg QD Plus Darolutamide 50 MR50 10/14 (71%) MR90 4/14 (29%) 25 50 50 50 50 50 50 90 90 90 90 0 • ctDNA molecular respo
Slide 28: Radiographic PFS Data Immature, but Early Landmark Analyses Promising
Radiographic Progression-Free Survival Data Are Immature, but Early Landmark Analyses Are Promising Rinzimetostat 400 mg QD Plus Darolutamide Dose Optimization: Time on Treatment Prior Treatments Abi + IO + R Abi + IO + P + O Abi + D Abi + D + R Abi + D Abi Abi + IO Landmark % rPFS Abi (Median Follo
Slide 29: Clearly Differentiated Safety Profile vs. Mevrometostat
Rinzimetostat 400 mg QD in Combination with Darolutamide in Post-Abiraterone mCRPC Demonstrate a Clearly Differentiated Safety Profile Rinzimetostat Adverse Event Comparison to Mevrometostat Mevrometostat 1250 mg BID Rinzimetostat 400 mg QD Mevrometostat 875 mg BID Rinzimetostat 400 mg QD (Fasted) +
Slide 30: Tolerability Compares Favorably to Competitor Regimens
Tolerability of Rinzimetostat 400 mg QD Plus Darolutamide Compares Favorably to Competitor Regimens Rinzimetostat Dose Modifications Comparison to Mevrometostat Mevrometostat 875 mg BID Mevrometostat 1250 mg BID Rinzimetostat 400 mg QD Fed + Enzalutamide Fasted + Enzalutamide + Darolutamide (n=14) (
Slide 31: Competitive Early Landmark rPFS with Differentiated Safety Profile
Rinzimetostat Demonstrates Competitive Early Landmark rPFS in Post- Abiraterone mCRPC and Does So with a Highly Differentiated Safety Profile Landmark rPFS and Safety Benchmark Comparisons Median Grade ≥3 Dose Reductions / 3-Month rPFS 4-Month rPFS 5-Month rPFS Follow-up TRAEs Discontinuations Mevro
Slide 32: Clinical Program Update and Next Steps: Next Steps and Registrational Strategy
Clinical Program Update and Next Steps Next Steps and Registrational Strategy
Slide 33: Himalayas-1: Global Phase 3 Study of Rinzimetostat with Darolutamide
Himalayas-1: Global Phase 3 Study of Rinzimetostat in Combination with Darolutamide in Patients with mCRPC Previously Treated with Abiraterone Rinzimetostat Global Phase 3 mCRPC Trial • Primary Endpoint: Rinzimetostat + • Patients with Darolutamide ─ Radiographic progression-free survival (rPFS) mCR
Slide 34: Steering Committee Comprised of Global Leaders in Prostate Cancer
Steering Committee Comprised of Global Leaders in Prostate Cancer Co-Chair – Karim Fizazi, MD PhD Arun Azad, MD PhD Institut Gustave Roussy - Paris Peter MacCallam Cancer Centre - Melbourne Chair – Matthew Smith, MD PhD Johann de Bono, MD PhD Mass General Hospital Cancer Center - Boston The Institut
Slide 35: Food Effect Cohort Prior to Initiation of Himalayas-1
Rinzimetostat Plus Darolutamide Is Being Evaluated in a Food Effect Cohort Prior to Initiation of Himalayas-1 Phase 3 Trial Food Effect Cohort: Design and Preliminary Data Food Effect Cohort Preliminary PSA Response 50 • Rinzimetostat is being studied in a food effect cohort to potentially enable do
Slide 36: Explored in Other Populations, Including Post-AR Inhibitor mCRPC
Rinzimetostat Is Being Explored in Other Patient Populations that Could Form the Basis of Future Phase 3 Trials, Including Post-AR Inhibitor mCRPC Rinzimetostat 400 mg QD Plus Darolutamide in Post-ARi mCRPC: Time on Treatment Landmark % rPFS (Median Follow-up of 4.8 Months) 3-Month 93% 4-Month 85% O
Slide 37: Commercial Potential for Himalayas-1 and Beyond
Commercial Potential for Himalayas-1 and Beyond
Slide 38: Abiraterone Remains the Leading ARPI Prescribed in the US
Abiraterone Remains the Leading ARPI Prescribed in the US, Accounting for Approximately Half of New ARPI Prescriptions Overview of Abiraterone Market Share Among ARPIs 60% 54% 51% 46% 40% 20% 0% Real-World Data Clinical Trial Data Prescription Data (US) (Global) (2025 US NRx) Abiraterone remains the
Slide 39: Significant Addressable Market in Post-Abiraterone mCRPC
Rinzimetostat Is Initially Pursuing a Significant Addressable Market in Post- Abiraterone mCRPC Rinzimetostat Total Addressable Market in Post-Abiraterone mCRPC Total Addressable Market in Post-Abiraterone mCRPC Potential Rinzimetostat Share US Annual Incidence Best-In-Disease Safety and Efficacy Pr
Slide 40: Independent Physician Market Research Shows Best-In-Class Potential
Independent Physician Market Research Demonstrates Rinzimetostat Has Best-In-Class Potential in Prostate Cancer Key Insights from Independent Market Research Testing Blinded Target Product Profiles (TPPs) Overview of US Prescriber Survey Key Takeaways Urologists and oncologists (n=18) surveyed acros
Slide 41: Potential to Address Multiple Large Market Opportunities in Prostate Cancer
Rinzimetostat Has the Potential to Address Multiple Large Market Opportunities in Prostate Cancer, with Several Development Opportunities in Other Solid Tumors Potential Rinzimetostat Commercial Opportunity (US Only) Future Development Opportunities 90,000 >$10 billion US Est. Annual US Incidence op
Slide 42: ORIC
OrIC
Slide 43: ORIC Pharmaceuticals: Dedicated to Overcoming Resistance In Cancer
ORIC Pharmaceuticals: Dedicated to Overcoming Resistance In Cancer • Potential best-in-class PRC2 inhibitor for prostate cancer • Potential best-in-class TKI for NSCLC with EGFR exon 20 and Validated Targets in High Unmet Need Populations EGFR PACC mutations • Rinzimetostat (ORIC-944) and enozertini
Slide 44: Thank You
OrIC \ Thank You